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Abstract  
AIM: To compare hospital costs of acute deep vein thrombosis (ADVT) treatment in two periods of time. Evidence 
of repercussions on reducing costs during successful treatment. Attention was given to the necessity, costs and 
effectiveness of diagnostic procedures, treatment and complications. 
METHODS: A retrospective analysis of data obtained from patients medical history in a period from 2000 to 2016. 
Model management and safe practice of ADVT care consisted of clinical examination, laboratory, colour Doppler 
and invasive diagnostics. In a treatment was used continuous infusion un-fractionated heparin for 40 patients from 
2000th till 2006th and low molecular weight heparin for 40 patients from 2006th till 2016th. All patients were 
converted to oral anticoagulants. 
RESULTS: When we look at the overall picture of improving the management model, safe practices and 
economic rationalization, we conclude that we offer better health service for the patients with ADVT at the 
moment, which relies on proven medical treatment trends. While we do not forget responsibility towards a society 
of which depends on treatment funding. 
CONCLUSION: The implementation of a conceptually new model of management of ADVT did not contribute rise 
of the desired outcomes, but it justified the positive economic viability of introduced changes at the Clinic of 
Vascular surgery than the previous concept.  
 
 
 
 
 
 
Introduction 
 
Regional Committee of the World Health 
Organization in September 1998, which includes 
delegations from ministries of states members, 
adopted the document "Health for All in the 21st 
century " and 21 objective criteria's (benchmarks) to 
be used for measuring progress in protecting and 
improving health. The goal 16, Quality management 
of health care, focuses on outcomes as the ultimate 
measure of quality. By 2010, State Members shall 
ensure that the management of health sector from 
the level of health programs to the level of individual 
health care is oriented on individual patient’s 
outcomes. The success of major public health 
strategies should be assessed regarding health 
outcomes and decisions regarding alternative 
strategies for dealing with individual health issues, 
increasingly be taken by comparing health outcomes 
and their cost- effectiveness. All countries should have 
a nationwide mechanism for continuous monitoring 
and the development of quality care for at least ten 
major health conditions, including measurement of 
health impact, cost-effectiveness and patient 
satisfaction [1]. 
Scientific research is aimed to answer 
questions and establish the facts about costs using 
different approaches to the treatment in two periods 
of time in treatment model of patients with ADVT at 
the Clinic of Vascular Surgery Sarajevo used in 
the period 2006th-2016th comparing with a model of 
treatment of patients with ADVT in the period 2000th-
2006th. 
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Comparison of the hospital costs and 
treatment models in the two periods of time. To 
prove which model of treatment had repercussions 
on the cost reduction. Researcher’s attention was 
also given to the necessity and effectiveness of 
diagnostic procedures and their costs and 
complications and their costs. 
The Council of Europe established a 
Commission of Experts on quality in 1995. This 
committee has created a large number of 
recommendations to the Minister of Health (adopted 
in 1997), which recommends that governments of 
member states establish systems to improve quality 
[2], as means that governments should develop 
policies and structures, where possible, which will 
support the development and implementation of a 
system for continuous assurance and improvement 
quality of health care at all levels. Resolution of the 
Council of Europe is based on the concept that the 
fundamental right of every individual in every 
community to get health care of good quality, which is 
defined in Article 11 of the European Social Letter on 
the right to health, while Article 3 of the Convention on 
Human Rights and Biomedicine requires that member 
states ensure residents' equitable access to health 
care of appropriate quality. Effects of any investment 
project can be evaluated and analysed, both 
regarding developing companies or institutions, as 
well as regarding the wider community. Institutions or 
companies as investors are usually interested only in 
direct economic effects of investments, which can be 
sufficiently accurately measured and expressed 
quantitatively, in contrast to the indirect where this is 
not possible. In this context, cost-effectiveness 
analysis is a tool for investment decisions. 
 
 
Patients and Methods 
 
The study was retrospective/prospective, 
descriptive and analytical, comparative, randomized 
and conducted in the Clinic of Vascular surgery 
Sarajevo Clinical Centre University of Sarajevo. The 
patients were divided into two groups. A group: 40 
patients with acute deep venous thrombosis in the 
period 2006th to 2016th. B group: 40 patients with 
acute deep venous thrombosis in the period from 
2000th to 2006th. Both groups were characterized by 
small variations according to age and comorbidities. 
Diagnostic evaluation of patients involved in- invasive 
and invasive procedures that each patient had been 
subjected. The clinical appearance of ADVT varied 
from absence of symptoms to massive swelling and 
cyanosis of the threatening venous gangrene 
(phlegmasia Cerulea dolens). Signs and symptoms 
suggestive for ADVT included pain, oedema, red-
ness, painful sensitivity during passive dorsiflexion 
(Homan's sign), fever, expressed superficial veins and 
peripheral cyanosis. Unfortunately, the diagnosis of 
ADVT based on clinical signs and symptoms is almost 
always wrong. More than 47 % of patients who 
reported to the vascular laboratory with the classical 
signs and symptoms were negative for ADVT after 
color-doppler (CD). Furthermore, more than 54% of 
patients with acute DVT had no specific clinical sign 
or symptom. The CD evaluation includes an 
assessment of lower limb venous compression, 
intra-luminal display characteristics including venous 
flow and luminal filling with blood.  
Of these, the most widely venous non-
compressibility used as an objective criterion for the 
diagnosis of ADVT. Non-compressibility is an 
excellent criterion at the proximal ADVT-e. D-dimer 
testing was incorporated into two general strategies. 
The first strategy used measure D-dimer to confirm 
an initial negative result of non-invasive testing and 
as a single procedure for reducing other diagnostics 
steps. Another strategy for D-dimer was in the triage 
of patients as an initial step for possible next 
diagnostic procedure. Because its limitations, D- dimer 
test was most valuable in combination with other 
diagnostic procedures, such as CD. 
Therefore, patients with normal values did 
not require further diagnostic treatments and thus 
reduced consumption of vascular laboratory 
resources. Venography, computerized tomographic 
venography and pulmonary scintigraphy were used 
as diagnostic supplements in specific cases. In the 
period 2000th-2006th treatment of 40 patients usually 
began with continuous intravenous infusion UFH. 
Treatment started with intra venous (i.v.) bolus of 
5.000 to 10.000 international units (IU) of UFH, 
followed by continuous infusion (perfusor) from 1.200 
to 1.500 IU UFH per 1 hour (or fixed dose of 30.000-
35.000 IU UFH in 24 hours), for 3 to 5 days. It was 
necessary to monitor the aPTT and INR. The aPTT 
had been targeted to 1.5 to 2.0 times from initial 
findings, and due this value doses of UFH increased 
or decreased. APTT was controlled every 6 hours 
after initiated therapy. Platelets were also counted 
and monitored due induced thrombocytopenia by 
heparin. When reduction or withdrawal of clinical 
signs of ADVT was noticed, we began with per oral 
anticoagulants, vitamin K antagonists (AVK), in a 
dose of 5-10 mg per 24 hours. The dose was 
titrated in the next 48-72 hours to target value of INR 
2.0-3.0. Once these values of the INR were 
accomplished, heparin was continued for 24- 48 
hours, and then turned off. In period of 2006th-
2016th treatment began with use of LMWH 
enoxaparin in dose of 1 mg per kg twice in 24 hours 
together with AVK 10-5 mg in 24hours. INR was first 
monitored in patient admission and once daily till 
target value of INR between 2 and 4 had been 
accomplished. 
Additional measures included treatment of any 
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concomitant diseases or conditions, oxygen therapy, 
and elevation of symptomatic extremity to reduce 
swelling and pain in. 
 
Statistical analysis  
All results were analysed by the statistical 
program SPSS version 16
th
 8 (SPSS Inc. Released 
2007. SPSS for Windows, Version 16.0. Chicago, 
SPSS Inc.). The results were analysed using t-test 
and 2 test for comparison between the investigated 
groups. The degree of correlation is tested using the 
correlation coefficient Pearson or Spearman. Finally, 
it would apply the appropriate models of regression 
analysis to determine the independent association of 
variables. Values of p < 0.05 will be considered 
statistically significant. 
 
 
Results 
 
Patients were divided into two equal groups 
regarding period, group A: 40 patients from 2006
th till 
2016
th and group B: 40 patients from 2000
th till 
2006
th
. There was the same gender ratio 18 woman 
and 22 men in both groups. In group A patients waited 
from appearance of first symptoms 55.7 hours = mean 
value (MV), (max = 96, min 8, Standard deviation 
(SD) = 33.59), in group B, MV = 87.3 hours (max = 
240, min = 12, SD 60.52).  
Table 1: General status and comorbidities of patients 
General status and comorbidities of 
patients 
Yes/
No 
A group 
40 patients 
B group 
40 patients 
ADVT 
2006
th
-2016
th
 
ADVT 
2000
th
 -2006
th
 
Frequency % Frequency % 
Nosocomial ADVT 
Y 8 20 14 35 
N 32 80 26 65 
Iatrogenic ADVT 
Y 3 7.5 3 7.5 
N 37 92.5 37 92.5 
ADVT after trauma 
Y 2 5 1 2.5 
N 28 95 39 97.5 
Complication of limb fracture 
Y 2 5 0 0 
N 38 95 40 100 
ADVT after childbirth 
Y 2 5 4 10 
N 38 95 36 90 
ADVT complication after Stroke 
Y 3 7.5 1 2.5 
N 37 92.5 39 97.5 
Stroke as complication of ADVT 
Y 1 2.5 0 0 
N 39 97.5 40 100 
Plegia (hemi, para, quadro) 
Y 3 7.5 1 2.5 
N 37 92.5 39 97.5 
Verified oncologic disease 
Y 9 22.5 2 5 
N 31 77.5 38 95 
Patient on hormone replacement 
therapy 
Y 2 5 2 5 
N 38 95 38 95 
Complication of elective surgery 
Y 4 10 0 0 
N 36 90 40 100 
Nosocomial bleeding 
Y 0 0 0 0 
N 40 100 40 100 
Nosocomial Pulmonary Embolism 
Y 4 10 2 5 
N 36 90 38 95 
Varicose veins of lower limbs 
Y 0 0 1 2.5 
N 40 100 39 97.5 
Complication of surgical treatment 
of varicose veins of lower limbs 
Y 0 0 1 2.5 
N 40 100 39 97.5 
Cardiac failure 
Y 3 7.5 1 2.5 
N 37 92.5 39 97.5 
Death outcome 
Y 1 2.5 1 2.5 
N 39 97.5 39 97.5 
 
 
 
Hospitalization in group A lasted 13.9 days = 
MV (max = 26, min = 2, SD = 5.37), in group B lasted 
17.3 days =MV (max = 25, min = 17.3, SD = 3.85). All 
costs were in Bosnia and Herzegovina currency 
Convertible Mark (KM). 
Table 2: The total cost of radiological diagnostics 
The total cost of 
radiological diagnostics 
Group N 
MV 
(KM) 
SD t p 
Color Doppler 
A 2006
th
-2016
th
 40 62.40 10.11 
16.15 0.000 
B 2000
th
-2006
th
 40 6.40 19.44 
Phlebography 
A 40 101.07 147.52 
4.33 0.000 
B 40 0.00 0.00 
Lung scintigraphy 
A 40 23.00 69.87 
2.08 0.041 
B 40 0.00 0.00 
Computed tomographic 
venography (CTV) 
A 40 18.97 67.48 
1.77 0.079 
B 40 0.00 0.00 
Heart ultrasound 
A 40 0.00 0.00 
1.00 0.320 
B 40 1.05 6.64 
 
Although mortality in patients with ADVT was 
very expected, it must be emphasized that it took 
place only in two deaths in the period from 2000th 
to 2016th in patients with diagnosed ADVT. The 
cause of deaths was confirmed with certainty because 
the autopsy procedures were carried out. 
Table 3: Total costs of laboratory diagnostics 
Total costs of 
laboratory diagnostics 
Group N 
MV 
(KM) 
SD SG t p 
Blood elements 
A 2006
th
-2016
th
 40 28.70 4.42 0.70 
0.82 0.413 
B 2000
th
-2006
th
 40 30.10 9.79 1.54 
Mineral status 
A 40 36.90 5.69 0.90 
0.82 0.413 
B 40 38.70 12.59 1.99 
D-Dimer 
A 40 18.90 3.97 0.62 
0.00 1.000 
B 40 18.90 5.69 0.90 
INR 
A 40 45.30 10.06 1.59 
5.92 0.00 
B 40 155.60 117.33 18.55 
APTT 
A 40 73.45 16.53 2.61 
5.92 0.00 
B 40 250.90 188.55 29.81 
 
The relationship between total costs and 
consumptions for analysis INR and APTT was 
investigated using Pearson correlation coefficient. 
Preliminary analyses were made to meet the 
assumptions of normality, linearity and homogeneity 
of variance. The strong positive correlation has been 
calculated between the consumption of the INR and 
the total cost (r = 0.530, n = 80, p <0.001) and 
consumption of the APTT and the total cost (r = 
0.530, n = 80, p <0.001; and between the length of 
hospitalization and the total cost (r = 0.932, n = 80, p 
<0.001.  
Table 4: Correlation analysis of costs 
Correlation analysis of costs  
Hospitalization 
in days 
INR APTT Total costs 
Hospitalization 
in days 
Pearson Correlation 1 0.331 0.330 0.932 
Sig. (2-tailed)  0.003 0.003 0.000 
N 80 80 80 80 
INR 
Pearson Correlation 0.331 1 0.997 0.530 
Sig. (2-tailed) 0.003  0.000 0.000 
N 80 80 80 80 
APTT 
Pearson Correlation 0.330 0.997 1 0.530 
Sig. (2-tailed) 0.003 0.000  0.000 
N 80 80 80 80 
Total costs 
Pearson Correlation 0.932 0.530 0.530 1 
Sig. (2-tailed) 0.000 0.000 0.000  
N 80 80 80 80 
 
The Strong mutual positive correlation was 
found between of INR and APTT, which explains the 
difference and model management settings in two 
periods of time. We have found a strong 
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correlation between the medium length of 
hospitalization consumptions and the INR (r = 0.331, 
n = 80, p = 0.003) and between the hospitalization 
and consumptions for the APTT (r = 0.330, n = 80, 
p = 0.003). Significant correlation of other procedures 
and the total cost were not found. 
 
 
Discussion 
 
Prevention and treatment of venous 
thromboembolism (VTE) is a challenge we face every 
day by doctors and hospitalized patients. According 
Virchow definition from the nineteenth century, 
which is valid to this day, there are three factors that 
influence the occurrence of VTE: stasis, an 
abnormality in the walls of blood vessels and changes 
in the coagulation system. Conditions associated with 
high risk for ADVT are: each surgical procedure in 
which general anesthesia lasts 30 minutes or more 
particularly those that are running on legs, 
postpartum period, failure of the left and right 
chambers of the heart, fractures, injuries, chronic 
insufficiency of deep veins under knee, prolonged bed 
rest, cancer, obesity and application of estrogen. 
VTE has two clinical entities: deep vein thrombosis 
(DVT) and pulmonary embolism (PE). Accurate 
diagnosis of VTE is very important. If VTE is not 
diagnosed and treated properly, it can be fatal or 
cause serious complications. 
The presence of VTE in the total population is 
1-2%. The disease occurs depending on age, ranging 
from 0.03% in people younger than 50 years, to 0.4% 
in people over 50 years. Most studies show equal 
representation of disease in both sexes. 
Approximately 50% of patients with proximal DVT also 
suffer from PE, which suggests that there is a 
strong link between the presence of PE and DVT in 
the lower extremities. In the USA, every year more 
than 250,000 people have been diagnosed with acute 
DVT in at least 50,000 of them suffer a pulmonary 
embolism. 
Standard treatment for ADVT considers 
anticoagulation with either LMWH or UFH as initially 
followed by treatment with an AVK as a long-term 
treatment. Cost-effectiveness of LMWH compared to 
UFH in the initial treatment of ADVT have been 
confirmed with consistent findings that therapy with 
LMWH has been more cost-effective compared to 
UFH. The major part of total costs for patients 
treatment were hospital days [5]. Care of patients 
participating in clinical trials regarding economic 
analyses and directly measuring the costs of 
interventions and outcomes may be so atypical that 
such results cannot be extrapolated to other settings 
[6]. Institutions differences, operational efficiency of 
health systems and participation in active clinical trials 
may differ significantly from usual practice [7]. The 
economic evaluation of treating patients with ADVT 
with LMWH as compared with UFH has been 
published for two clinical trials [8, 9], one cost 
minimization study, and two cost-effectiveness 
analyses [10, 11]. Hull et al. showed that the LMWH 
strategy (tinzaparin, RR of recurrent thrombosis of 
41%) dominates the UFH strategy; i.e. Recurrent 
thrombo-embolism with LMWH treatment strategy had 
41 fewer cases of and 49 fewer deaths occur per 
1,000 patients than UFH treatment strategy with 
savings in the health care system $482,000 [8] (all 
patients were in hospital). If 37% of the patients had 
been treated outside the hospital's savings would 
increase to $1,096,370 [9]. On the contrary to 
grounded opinions, the findings from Christopher J 
Pannucci, Lukasz Swistun, John K MacDonald, Peter 
K Henke, Benjamin S Brooke (Annals of Surgery 2017 
January 19) question routine use of primary 
chemoprophylaxis in the surgical population. "These 
data argue strongly for a precision medicine approach 
to VTE chemoprophylaxis, where the intervention is 
guided by the risk and benefit relationship at the 
patient level," write Christopher J. Pannucci, MD, a 
plastic surgeon and an assistant professor of surgery 
at the University of Utah in Salt Lake City, and 
colleagues. The analysis of 13 studies included 
14,776 surgical patients, who received "mechanical" 
prophylaxis (UFH, LMWH, direct factor Xa inhibitors, 
direct thrombin inhibitors, warfarin, dextran, and 
acetylsalicylic acid). Patients were stratified based on 
Caprini scores for VTE risk; there are 14- fold 
variation in risk between 0.7% - 10.7%. The incidence 
of VTE increased with increasing Caprini 
scores."Patients with Caprini scores of ≤ 6, which 
includes ~75% of surgical patients, have an 
unfavourable or unknown risk/benefit relationship 
with chemoprophylaxis." "A 'one-size-fits-all 
approach' doesn't always make sense," Dr Pannucci 
said in a related press release. "A healthy 35-year-
old is very different from someone who is 85 and 
has a history of clots. Our research indicates that 
there could be a substantial number of people who are 
being over-treated" [12]. 
 In conclusion, the implementation of a 
conceptually new model of management of ADVT did 
not contribute rise of the desired outcomes but it 
justified the positive economic viability of introduced 
changes at the Clinic of Vascular surgery Sarajevo 
than the previous concept. Departments of health 
services through fundamental changes of services 
should aim from the offer, health services which are 
determined by health service providers, to the 
demands, expectations and needs of patients. 
However, health services have not unlimited 
resources and should, therefore, strive for optimal 
balance taking into account the needs and desires of 
patients, expert assessments and the availability of 
resources. Ideal balance can be determined through 
the processes of communication and negotiation and 
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must meet the quality relationship between 
client/customer as patients/health professionals. 
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